
Another huge quarter for biotech flotations
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.